Proximal Risk for Suicide in Adolescents
Launched by OREGON HEALTH AND SCIENCE UNIVERSITY · May 1, 2024
Trial Information
Current as of November 14, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Proximal Risk for Suicide in Adolescents," is studying how wearable technology can help monitor the mental health of teenagers who are at risk for suicide. The goal is to see if using devices that track things like heart rate and activity levels can help healthcare providers identify when a young person’s condition is getting worse. By catching these changes early, doctors can intervene sooner and provide personalized support to help manage suicidal thoughts or behaviors.
To participate in this study, adolescents aged 13 to 17 who are being treated in an emergency department or psychiatric unit for suicidal thoughts or attempts may be eligible. However, those who are very agitated, not medically cleared, or have certain conditions (like significant developmental delays) won’t be included. If selected, participants can expect to wear a device that will help doctors keep an eye on their mental health over time, which could lead to better care and support. This trial is currently looking for participants, and it aims to improve how we understand and respond to mental health crises in teens.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • subjects aged 13-17 years
- • presenting to the ED or inpatient psychiatric unit with a chief complaint of acute suicidality or attempt.
- Exclusion Criteria:
- • acutely agitated patients per the treating physician
- • adolescents who are not medically cleared from a suicide attempt
- • no legally authorized representative available to provide consent
- • parental report of significant developmental delay or autism diagnosis
- • prisoners
- • non-English speaking.
About Oregon Health And Science University
Oregon Health and Science University (OHSU) is a leading academic medical center dedicated to advancing health through research, education, and patient care. As a prominent sponsor of clinical trials, OHSU leverages its extensive expertise in various medical fields to facilitate innovative research aimed at improving patient outcomes. The institution is committed to ethical standards and rigorous scientific methodologies, fostering collaborations that enhance the development of new therapies and interventions. With a focus on translating research discoveries into clinical practice, OHSU plays a pivotal role in shaping the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Portland, Oregon, United States
Patients applied
Trial Officials
David Sheridan, MD
Principal Investigator
Oregon Health and Science University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported